MedTrace Logo

Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)

NCT04921930 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-20

No results posted yet for this study

Summary

This dose-escalation study is aimed at investigating a novel application for artesunate in the treatment of Friedreich ataxia. It will evaluate this novel application of oral artesunate using a surrogate biological marker as primary endpoint in a phase I-II open trial

Conditions

  • Friedreich Ataxia

Interventions

DRUG

Artesunate Oral Product

Dose escalation intake of artesunate

Sponsors & Collaborators

  • Imagine Institute

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Principal Investigators

  • Arnold Munnich, MD · Institut National de la Santé Et de la Recherche Médicale, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-06
Primary Completion
2024-04-17
Completion
2024-04-17

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04921930 on ClinicalTrials.gov